While targeting α-SMA gene expression has been advocated for inhibiting myofibroblast differentiation to reduce tissue fibrosis [31], this strategy may not be useful in treating skeletal muscle fibrosis associated with DMD. Here, ACTA1 is linked to Duchenne muscular dystrophy.